NASDAQ · PAVM
PAVmed Inc.
$1.97-$0.11 (-5.29%)
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.07% below the high.
Loading market information…
NASDAQ · BLCM · USD
Stock price, earnings
Quote as of Mar 4, 2024, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bellicum Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 24, 2022 |
| -$0.27+32.5% vs estimate |
| $500.00K+100.0% vs estimate |
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.97-$0.11 (-5.29%)
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.07% below the high.
$0.73-$0.03 (-3.84%)
Anew Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.79% below the high.
$1.85+$0.23 (+14.2%)
BiomX Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.5% below the high.
$0.32-$0.17 (-34.28%)
InVivo Therapeutics Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 86.64% below the high.
$0.04-$0.02 (-27.27%)
Impel Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.05% below the high.
$0.66-$0.21 (-24.02%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.27% below the high.
$0.02+$0.00 (+27.39%)
BIOLASE, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.97% below the high.
$0.02$0.00 (0.0%)
Peak Bio, Inc.: Healthcare · Biotechnology.
